Thursday, 21 April 2022

Histone Deacetylase Inhibitors: An Innovative Revolution as Epigenetic Modifiers | Chapter 11 | New Horizons in Medicine and Medical Research Vol. 3

 

The target-based epigenetic mechanisms, as well as the existing and potential therapeutic relevance of HDACIs in many malignant and non-malignant disorders, are discussed in this review article. Acetylation and deacetylation of histone proteins are important epigenetic changes that affect gene transcription and expression. Acetylation stimulates gene expression by transforming chromatin into a less compact, transcriptionally active state, which is catalysed by histone acetyl transferases enzymes. Histone deacetylase enzymes catalyse the deacetylation of chromatin, which causes it to condense into a closed structure. Transcriptional factors are unable to access DNA as a result, and gene expression is reduced. For normal gene expression, the activity of HATs and HDACS must be balanced. Hypoacetylation, tight chromatin structure, and gene repression can all arise from increased HDAC activity. A number of malignancies and other diseases, including neurological disorders, are characterised by erroneous gene repression. Histone Deacetylase Inhibitors have the ability to reverse the silence of pathogenic genes by restoring histone acetylation equilibrium. As a result, HDACIs function as epigenetic modifiers, altering gene expression without changing DNA sequence. Valproic acid and other HDACIs have shown promise in diseases other than cancer, including neurological diseases, mental disorders, autoimmune disorders, inflammatory diseases, diabetes mellitus, cardiovascular disease, and AIDS. HDACIs authorised by the FDA include Vorinostat, Belinostat, Panobinostat, and Romidepsin. Many more drugs, including valproic acid, are at various stages of clinical testing. Medical journal articles and the Medline bibliographic database were used as data sources.

Author(S) Details


Pinki Vishwakarma
Department of Pharmacology, LLRM Medical College, Meerut - 250004, U.P., India.

Alok Kumar
Department of Forensic Medicine & Toxicology, RIMS & R Saifai, Etawah -206001, U.P., India.

Alok Kumar
Department of Forensic Medicine & Toxicology, RIMS & R Saifai, Etawah -206001, U.P., India.

Meena Garg
Department of Pharmacology, LLRM Medical College, Meerut - 250004, U.P., India.

K. K. Saxena
Department of Pharmacology, LLRM Medical College, Meerut - 250004, U.P., India.

View Book:-
https://stm.bookpi.org/NHMMR-V3/article/view/6340


No comments:

Post a Comment